Developer docs
API playgroundTry for free, no card

Search company profiles

Apexigen

Full company profile

uuid000262u

Namestring
Apexigen
Legal namestring
Apexigen, Inc.
Websiteurl
apexigen.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Apexigen was a clinical-stage biopharmaceutical company founded in 2009 by Xiaodong Yang, M.D., Ph.D., and headquartered in San Carlos, California. The company focused on discovering and developing innovative antibody therapeutics for oncology, with a particular emphasis on patients who had progressed on PD-(L)1 checkpoint inhibitors. Its lead clinical asset was sotigalimab, a CD40 agonist antibody positioned as a potentially first- and best-in-class immuno-oncology candidate demonstrating anti-cancer activity in this hard-to-treat population.

The company's core technology was the APXiMAB antibody-discovery platform, described as clinically and commercially validated and capable of generating novel humanized antibodies optimized for targeted payload delivery in antibody-drug conjugate (ADC) development. The platform integrated four components: novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site-specific conjugation chemistries, and optimized payloads. As a pre-revenue clinical-stage company, Apexigen generated no commercial product revenue and funded operations through venture capital financings, a SPAC-related PIPE transaction, and bridge private placements.

Apexigen was acquired by Pyxis Oncology in August 2023 in an all-stock transaction valued at approximately $10.7 million, with Apexigen shareholders receiving a 10% stake in the combined entity. The transaction integrated APXiMAB with Pyxis Oncology's FACT platform (licensed from Pfizer) to create an end-to-end ADC development capability. Prior to the acquisition, the company had pursued a public listing via a business combination with Brookline Capital Acquisition Corp. announced in March 2022, which raised approximately $73 million in gross proceeds, followed by a $2.8 million bridge private placement in January 2023. Following the acquisition, sotigalimab was renamed PYX-107 within Pyxis Oncology's pipeline.

Short descriptiontext

Apexigen was a clinical-stage biopharmaceutical company developing antibody therapeutics for oncology, with lead candidate sotigalimab (a CD40 agonist) and the APXiMAB antibody-discovery platform. The company was acquired by Pyxis Oncology in August 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
antibody therapeutics, immuno-oncology, antibody-drug conjugates, clinical-stage biopharmaceuticals, CD40 agonists
Industry3 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAKAFAH
Neuro-Oncology
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage company focused on developing antibody therapeutics for oncology. Revenue would be generated upon successful FDA approval and commercialization of drug candidates including sotigalimab (CD40 agonist).

ir.pyxisoncology.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1APXiMAB
Description

A validated antibody-discovery platform used for generating novel humanized antibodies for targeted payload delivery in oncology therapeutics.

ir.pyxisoncology.com
Core offering1 text field

Apexigen was a clinical-stage biopharmaceutical company that discovered and developed antibody therapeutics for oncology. Its core offering was the proprietary APXiMAB antibody-discovery platform for generating novel humanized antibodies, and its lead clinical asset sotigalimab, a CD40 agonist antibody designed to treat patients who progressed on PD-(L)1 inhibitors. The company operated through clinical trials targeting regulatory approval pathways for oncology drug candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors
Product overview1 text field

Apexigen was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. The company operated with its core APXiMAB platform for antibody discovery and developed sotigalimab (now PYX-107), a CD40 agonist antibody candidate. Following its acquisition by Pyxis Oncology in August 2023, the company's platform capabilities were integrated to enhance Pyxis Oncology's ADC development pipeline.

Product and service1 record
1APXiMAB Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthers
Description

Legal advisor to Pyxis Oncology during the acquisition transaction.

Strategic tierMinorTypeOthers
Description

Financial advisor to Apexigen during the acquisition transaction.

Strategic tierMinorTypeOthers
Description

Legal advisor to Apexigen during the acquisition transaction.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Computational drug discovery company with proprietary platforms for antibody design and optimization. Comparable technology-driven approach to antibody discovery, though broader therapeutic focus beyond oncology.

TypeEmerging player
Description

Clinical-stage oncology company developing next-generation ADCs with proprietary linker and payload technologies. Comparable emerging ADC platform company with overlapping approach to differentiated antibody-payload conjugate design.

TypeDirect peer
Description

Clinical-stage immuno-oncology company leveraging computational platforms to identify novel drug targets and develop therapeutic antibodies. Similar clinical stage, oncology focus, and platform-driven antibody discovery approach.

TypeDirect peer
Description

Apexigen's acquirer (NASDAQ: PYXS); clinical-stage company developing next-generation ADC and immuno-oncology therapeutics. Direct peer given identical oncology focus, ADC platform strategy, and now integrated CD40 agonist (PYX-107) asset formerly known as sotigalimab.

TypeBroad incumbent
Description

Large pharmaceutical company developing selicrelumab (CD40 agonist) and multiple immuno-oncology assets. Direct competitor in the CD40 agonist space with vastly greater resources, commercial reach, and competing pipeline programs.

TypeBroad incumbent
Description

Established ADC-focused oncology company with multiple approved and clinical-stage products. Broader incumbent in ADC space with validated platform that overlaps with Apexigen/Pyxis's combined antibody-discovery and conjugation capabilities.

TypeDirect peer
Description

Clinical-stage oncology company developing conditionally activated immunotherapies and antibody therapeutics. Similar clinical stage, focus on improving therapeutic index of immuno-oncology agents, and target patient population of difficult-to-treat cancers.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) with proprietary platforms including novel linkers and payloads. Highly comparable ADC platform strategy to Apexigen's APXiMAB-enabled ADC development efforts.

TypeDirect peer
Description

Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune agonists—directly analogous mechanism to Apexigen's CD40 agonist approach. Comparable stage, size, and oncology focus.

10Surface Oncology
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing therapeutics targeting the tumor microenvironment. Similar size, clinical stage, and focus on next-generation immunotherapy approaches for cancer patients resistant to checkpoint inhibitors.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apexigen

Oncology Biopharmaceuticalsapexigen.com

Apexigen was a clinical-stage biopharmaceutical company developing antibody therapeutics for oncology, with lead candidate sotigalimab (a CD40 agonist) and the APXiMAB antibody-discovery platform. The company was acquired by Pyxis Oncology in August 2023.

What Apexigen does

Apexigen was a clinical-stage biopharmaceutical company founded in 2009 by Xiaodong Yang, M.D., Ph.D., and headquartered in San Carlos, California. The company focused on discovering and developing innovative antibody therapeutics for oncology, with a particular emphasis on patients who had progressed on PD-(L)1 checkpoint inhibitors. Its lead clinical asset was sotigalimab, a CD40 agonist antibody positioned as a potentially first- and best-in-class immuno-oncology candidate demonstrating anti-cancer activity in this hard-to-treat population.

The company's core technology was the APXiMAB antibody-discovery platform, described as clinically and commercially validated and capable of generating novel humanized antibodies optimized for targeted payload delivery in antibody-drug conjugate (ADC) development. The platform integrated four components: novel humanized antibody generation capabilities, an expanded library of linkers with improved stability, site-specific conjugation chemistries, and optimized payloads. As a pre-revenue clinical-stage company, Apexigen generated no commercial product revenue and funded operations through venture capital financings, a SPAC-related PIPE transaction, and bridge private placements.

Apexigen was acquired by Pyxis Oncology in August 2023 in an all-stock transaction valued at approximately $10.7 million, with Apexigen shareholders receiving a 10% stake in the combined entity. The transaction integrated APXiMAB with Pyxis Oncology's FACT platform (licensed from Pfizer) to create an end-to-end ADC development capability. Prior to the acquisition, the company had pursued a public listing via a business combination with Brookline Capital Acquisition Corp. announced in March 2022, which raised approximately $73 million in gross proceeds, followed by a $2.8 million bridge private placement in January 2023. Following the acquisition, sotigalimab was renamed PYX-107 within Pyxis Oncology's pipeline.

Apexigen firmographics

Firmographics
Name
Apexigen
Legal name
Apexigen, Inc.
Website
https://apexigen.com
Company type
Private
Founded year
2009
Operating status
Acquired
Headcount range
1–10 employees
Short description
Apexigen was a clinical-stage biopharmaceutical company developing antibody therapeutics for oncology, with lead candidate sotigalimab (a CD40 agonist) and the APXiMAB antibody-discovery platform. The company was acquired by Pyxis Oncology in August 2023.
Ownership category
akta.pro rank

Apexigen industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAKAFAH
Neuro-Oncology

Keywords

  • Antibody therapeutics
  • Immuno-oncology
  • Antibody-drug conjugates
  • Clinical-stage biopharmaceuticals
  • CD40 agonists

Where Apexigen is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Markets served

Apexigen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Drug Development and Commercialization: Pre-revenue clinical-stage company focused on developing antibody therapeutics for oncology. Revenue would be generated upon successful FDA approval and commercialization of drug candidates including sotigalimab (CD40 agonist).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Apexigen product offering

Product offering

Core offering

Apexigen was a clinical-stage biopharmaceutical company that discovered and developed antibody therapeutics for oncology. Its core offering was the proprietary APXiMAB antibody-discovery platform for generating novel humanized antibodies, and its lead clinical asset sotigalimab, a CD40 agonist antibody designed to treat patients who progressed on PD-(L)1 inhibitors. The company operated through clinical trials targeting regulatory approval pathways for oncology drug candidates.

Product overview

Apexigen was a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology. The company operated with its core APXiMAB platform for antibody discovery and developed sotigalimab (now PYX-107), a CD40 agonist antibody candidate. Following its acquisition by Pyxis Oncology in August 2023, the company's platform capabilities were integrated to enhance Pyxis Oncology's ADC development pipeline.

Differentiator

Problem solved

Functional benefit

Brands

  • APXiMAB: A validated antibody-discovery platform used for generating novel humanized antibodies for targeted payload delivery in oncology therapeutics.

Products and services

  • APXiMAB Platform

Quantifiable outcome

  • Demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors

Companies that use Apexigen

Customer profile

Segments1 record

Ideal customer profiles1 record

Apexigen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Apexigen partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Apexigen competitors and assessment

Company assessment

Emerging players

  • Schrödinger: Computational drug discovery company with proprietary platforms for antibody design and optimization. Comparable technology-driven approach to antibody discovery, though broader therapeutic focus beyond oncology.
  • ProfoundBio: Clinical-stage oncology company developing next-generation ADCs with proprietary linker and payload technologies. Comparable emerging ADC platform company with overlapping approach to differentiated antibody-payload conjugate design.

Direct peers

  • Compugen: Clinical-stage immuno-oncology company leveraging computational platforms to identify novel drug targets and develop therapeutic antibodies. Similar clinical stage, oncology focus, and platform-driven antibody discovery approach.
  • Pyxis Oncology: Apexigen's acquirer (NASDAQ: PYXS); clinical-stage company developing next-generation ADC and immuno-oncology therapeutics. Direct peer given identical oncology focus, ADC platform strategy, and now integrated CD40 agonist (PYX-107) asset formerly known as sotigalimab.
  • Werewolf Therapeutics: Clinical-stage oncology company developing conditionally activated immunotherapies and antibody therapeutics. Similar clinical stage, focus on improving therapeutic index of immuno-oncology agents, and target patient population of difficult-to-treat cancers.
  • Mersana Therapeutics: Clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) with proprietary platforms including novel linkers and payloads. Highly comparable ADC platform strategy to Apexigen's APXiMAB-enabled ADC development efforts.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody conjugates (ISACs) that combine tumor-targeting antibodies with immune agonists—directly analogous mechanism to Apexigen's CD40 agonist approach. Comparable stage, size, and oncology focus.
  • Surface Oncology: Clinical-stage immuno-oncology company developing therapeutics targeting the tumor microenvironment. Similar size, clinical stage, and focus on next-generation immunotherapy approaches for cancer patients resistant to checkpoint inhibitors.

Broad incumbents

  • Roche: Large pharmaceutical company developing selicrelumab (CD40 agonist) and multiple immuno-oncology assets. Direct competitor in the CD40 agonist space with vastly greater resources, commercial reach, and competing pipeline programs.
  • ImmunoGen: Established ADC-focused oncology company with multiple approved and clinical-stage products. Broader incumbent in ADC space with validated platform that overlaps with Apexigen/Pyxis's combined antibody-discovery and conjugation capabilities.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Apexigen social profiles

Digital presence

Apexigen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apexigen leadership team

Management profile

Number of profiles

Apexigen funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apexigen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apexigen

What does Apexigen do?

Apexigen was a clinical-stage biopharmaceutical company that discovered and developed antibody therapeutics for oncology. Its core offering was the proprietary APXiMAB antibody-discovery platform for generating novel humanized antibodies, and its lead clinical asset sotigalimab, a CD40 agonist antibody designed to treat patients who progressed on PD-(L)1 inhibitors. The company operated through clinical trials targeting regulatory approval pathways for oncology drug candidates.

Is Apexigen a public or private company?

Apexigen is a private company. It is classified as corporate owned and is currently acquired.

When was Apexigen founded?

Apexigen was founded in 2009. It employs 1 to 10 people.

Where is Apexigen based?

Apexigen is headquartered in San Carlos, United States, in the North America region.

How does Apexigen make money?

One revenue line is on record: drug Development and Commercialization.

Who are Apexigen's main competitors?

Emerging players on record are Schrödinger and ProfoundBio. Direct peers are Compugen, Pyxis Oncology, Werewolf Therapeutics, Mersana Therapeutics, Bolt Biotherapeutics and Surface Oncology. Broad incumbents are Roche and ImmunoGen.

Does Apexigen have an API?

No public API is recorded for Apexigen.

What industry is Apexigen in?

Apexigen's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PyxisoncologyPyxis Oncology Successfully Completes Acquisition of ApexigenPyxis Oncology announced the successful completion of its acquisition of Apexigen, a transaction valued at approximately $10.7 million that adds to Pyxis Oncology's capabilities in antibody-drug conjugate (ADC) innovation. This acquisition is set to enhance their pipeline, especially with the addition of a Phase 2 candidate, sotigalimab, which shows promise for treating certain cancers. The combined company is now positioned with an end-to-end system for developing next-generation ADC candidates.BenzingaPyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst - Pyxis Oncology (NASDAQ:PYXS)RBC Capital Markets initiated coverage on Pyxis Oncology with an Outperform rating and a $7 price target. The company recently acquired Apexigen in an all-stock deal valued at about $10.7 million. Analysts see potential from its ADC platform and I/O assets, though they note competition and toxicity risks.PR NewswireShareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis OncologyAdemi LLP is investigating Apexigen, Inc. regarding its merger transaction with Pyxis Oncology to determine if the board fulfilled fiduciary duties and secured a fair price for shareholders. The investigation highlights that public stockholders are set to receive an implied value of $0.64 per share while insiders benefit from change-of-control arrangements. Ademi alleges the transaction agreement unreasonably limits competing bids through significant penalties.BenzingaSmall SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M - Pyxis Oncology (NASDAQ:PYXS)Pyxis Oncology Inc agreed to acquire Apexigen Inc in an all-stock transaction for an implied value of $0.64 per share, representing a total enterprise value of approximately $16 million. Apexigen, which went public via a SPAC in 2021, had announced in February that it was evaluating strategic alternatives after reducing its workforce by 55%. The acquisition will add humanized antibody generation technology to Pyxis Oncology's ADC (antibody-drug conjugate) platform, with the transaction expected to close by mid-2023 and the combined company continuing to trade on Nasdaq under the PYXS ticker symbol.GlobeNewswirePyxis Oncology to Acquire ApexigenPyxis Oncology agreed to acquire Apexigen in an all-stock deal valued at $0.64 per Apexigen share, for an enterprise value of about $16 million. The acquisition adds Apexigen's APXiMAB antibody platform to Pyxis's ADC toolkit, with the deal expected to close by mid-2023.ContractpharmaPyxis Oncology to Acquire Apexigen in $16M DealPyxis Oncology agreed to acquire Apexigen for approximately $16 million, adding humanized antibody generation to its ADC toolkit. The deal expands Pyxis's pipeline into Phase 2 trials for sotigalimab, a CD40 agonist evaluated in over 500 patients. The acquisition aims to combine Apexigen's APXiMAB platform with Pyxis's FACT technology.GlobeNewswirePyxis Oncology to Acquire ApexigenPyxis Oncology agreed to acquire Apexigen in an all-stock deal valued at $0.64 per Apexigen share, for an enterprise value of about $16 million. The acquisition adds Apexigen's APXiMAB antibody platform to Pyxis's ADC toolkit, with the deal expected to close by mid-2023.BioSpacePyxis Oncology to Acquire ApexigenPyxis Oncology announced a definitive all-stock agreement to acquire Apexigen for an implied value of $0.64 per share, totaling approximately $16 million in enterprise value. The transaction combines Pyxis's FACT ADC toolkit with Apexigen's APXiMAB antibody platform and adds the Phase 2 candidate sotigalimab to Pyxis's pipeline while extending its cash runway into 2025. The deal is expected to close by mid-2023 pending customary conditions, including stockholder approval.PyxisoncologyPyxis Oncology to Acquire ApexigenPyxis Oncology announced a definitive agreement to acquire clinical-stage biopharmaceutical company Apexigen in an all-stock transaction valued at approximately $16 million. The acquisition integrates Apexigen's APXiMAB antibody platform and the sotigalimab pipeline into Pyxis Oncology's existing ADC toolkit, aiming to expand their capabilities in immuno-oncology while extending Pyxis's cash runway into 2025.BioSpaceApexigen Announces Review of Strategic Alternatives and RestructuringApexigen announced it engaged Ladenburg Thalmann & Co. to evaluate strategic alternatives, including acquisition, sale, merger, divestiture, licensing, or other transactions. The company will also restructure to extend its cash runway, cutting its workforce by 55%. No update will be disclosed until definitive agreements are reached.